Aprepitant Medical Valley: Uses, Dosage & Side Effects

What Is Aprepitant Medical Valley and What Is It Used For?

Quick Answer: Aprepitant Medical Valley is a generic antiemetic medication containing aprepitant, an NK1 receptor antagonist. It is used to prevent nausea and vomiting caused by cancer chemotherapy (both highly and moderately emetogenic regimens) and to prevent postoperative nausea and vomiting (PONV). It is used as part of a combination antiemetic regimen.

Aprepitant Medical Valley contains aprepitant, a selective, high-affinity antagonist of the human substance P/neurokinin 1 (NK1) receptor. This medication belongs to a class of antiemetics that target a fundamentally different pathway from traditional anti-nausea drugs, making it a valuable addition to combination antiemetic therapy. Aprepitant was originally developed by Merck & Co. (MSD) and first approved under the brand name Emend by the U.S. Food and Drug Administration (FDA) in 2003 and by the European Medicines Agency (EMA) in 2004. Aprepitant Medical Valley is a bioequivalent generic version manufactured by Medical Valley.

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most feared side effects among cancer patients, and effective prevention is critical for maintaining quality of life, treatment adherence, and nutritional status during cancer treatment. The emetic response to chemotherapy involves multiple neurotransmitter pathways, and no single antiemetic drug can completely block all of these pathways. This is why international guidelines from the Multinational Association of Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN) all recommend a multi-drug antiemetic approach for patients receiving emetogenic chemotherapy.

The vomiting reflex involves two main phases after chemotherapy administration. The acute phase occurs within the first 24 hours and is primarily mediated by serotonin (5-HT3) release from enterochromaffin cells in the gut. The delayed phase occurs from approximately 24 hours to 5 days after chemotherapy and is primarily mediated by substance P acting on NK1 receptors in the brainstem. While 5-HT3 antagonists such as ondansetron are highly effective against acute-phase CINV, they have limited efficacy against delayed-phase symptoms. Aprepitant was developed specifically to address this gap by blocking NK1 receptors, providing protection against both acute and delayed emesis.

Approved Indications

Aprepitant Medical Valley is approved for the following clinical uses by major regulatory authorities:

• Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC): Including cisplatin-based regimens, which are among the most emetogenic chemotherapy drugs. Aprepitant is given as part of a combination regimen with a 5-HT3 receptor antagonist and dexamethasone.
• Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (MEC): For regimens that have a moderate risk of causing nausea and vomiting, such as certain carboplatin, cyclophosphamide, doxorubicin, or irinotecan combinations.
• Prevention of postoperative nausea and vomiting (PONV): In adults at risk of PONV, aprepitant 40 mg given orally within 3 hours before induction of anaesthesia has been shown to reduce the incidence of postoperative nausea and vomiting.

The World Health Organization (WHO) has included aprepitant on the WHO Model List of Essential Medicines, recognising its importance as a key antiemetic for patients undergoing chemotherapy treatment worldwide.

Mechanism of Action

Aprepitant is a selective, high-affinity antagonist of the human substance P/neurokinin 1 (NK1) receptor. Substance P is a neuropeptide belonging to the tachykinin family that plays a critical role in the emetic reflex, particularly during the delayed phase of CINV. Substance P is released both peripherally (from vagal afferent nerve terminals in the gut) and centrally (in the nucleus tractus solitarius and area postrema of the brainstem) in response to emetogenic stimuli.

Aprepitant crosses the blood-brain barrier and occupies NK1 receptors in the brain. Positron emission tomography (PET) studies have demonstrated that the standard doses of aprepitant (125 mg on Day 1, 80 mg on Days 2 and 3) achieve greater than 90% NK1 receptor occupancy in the brain. This high level of receptor blockade prevents substance P from triggering the emetic reflex at the central level, providing significant antiemetic protection that complements the peripheral actions of 5-HT3 antagonists and corticosteroids.

Unlike the 5-HT3 antagonists, which primarily target the acute phase of CINV, the NK1 receptor-mediated pathway is particularly important in the delayed phase. This explains why the addition of aprepitant to a 5-HT3 antagonist and dexamethasone regimen produces the greatest incremental benefit during days 2 through 5 after chemotherapy, when delayed nausea and vomiting are most problematic. However, aprepitant also provides additional protection during the acute phase, likely because both serotonin and substance P pathways contribute to acute emesis.

What Should You Know Before Taking Aprepitant Medical Valley?

Quick Answer: Before starting aprepitant, inform your doctor about all medications you take, especially warfarin, hormonal contraceptives, and corticosteroids. Aprepitant is a moderate CYP3A4 inhibitor and inducer, meaning it can alter the levels of many other drugs. It should be used with caution in patients with severe liver disease and is not recommended during pregnancy.

Before your oncologist prescribes aprepitant as part of your antiemetic regimen, a comprehensive review of your medical history, concurrent medications, and overall health status is essential. While aprepitant is generally well tolerated, its pharmacokinetic interactions with the cytochrome P450 enzyme system mean that it can affect the metabolism of several commonly used medications. Understanding these considerations before starting treatment helps ensure both safety and optimal effectiveness.

Contraindications

Aprepitant Medical Valley should not be used in the following situations:

• Hypersensitivity: Known allergy to aprepitant or any of the excipients in the capsule formulation. Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported during post-marketing surveillance, though they are very rare.
• Concomitant use with pimozide: Aprepitant inhibits CYP3A4, which could raise plasma concentrations of pimozide, a CYP3A4 substrate. Elevated pimozide levels can cause serious or life-threatening cardiac arrhythmias, including QT prolongation and torsades de pointes. This combination is strictly contraindicated.
• Concomitant use with terfenadine, astemizole, or cisapride: These medications are CYP3A4 substrates whose plasma levels could be dangerously elevated by CYP3A4 inhibition, increasing the risk of serious cardiac adverse effects.

Warnings and Precautions

Special caution is required when using aprepitant in the following situations:

• CYP3A4 interactions: Aprepitant is a moderate inhibitor of CYP3A4 during the 3-day treatment period and a mild inducer of CYP3A4 thereafter. This dual effect can transiently increase and then decrease plasma levels of drugs metabolised by CYP3A4. Dose adjustments of co-administered corticosteroids (dexamethasone, methylprednisolone) are mandatory.
• Warfarin and other vitamin K antagonists: Aprepitant can induce CYP2C9, leading to a decrease in S-warfarin levels approximately 2 weeks after a 3-day course of aprepitant. Patients on chronic warfarin therapy should have their international normalised ratio (INR) monitored closely during the 2-week period following each chemotherapy cycle with aprepitant, particularly at 7 to 10 days after aprepitant initiation.
• Hormonal contraceptives: Aprepitant may reduce the effectiveness of hormonal contraceptives (pills, patches, rings, and implants) by inducing CYP3A4 and thereby increasing the metabolism of ethinyl estradiol and progestogens. Alternative or additional non-hormonal contraceptive methods (such as barrier methods) should be used during treatment with aprepitant and for 28 days after the last dose.
• Severe hepatic impairment: There are limited clinical data on the use of aprepitant in patients with severe hepatic impairment (Child-Pugh score >9). Aprepitant should be used with caution in these patients. No dose adjustment is needed for mild to moderate hepatic impairment.
• Renal impairment: No dose adjustment is required for patients with renal impairment, including those with end-stage renal disease on haemodialysis.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of aprepitant in pregnant women. Animal reproduction studies have not demonstrated clear evidence of teratogenicity, but embryo-foetal toxicity was observed at maternally toxic doses in animal models. As a precautionary measure, aprepitant should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the foetus. Women of childbearing potential should be advised to use effective contraception during treatment and for at least one month after the last dose.

It is not known whether aprepitant is excreted in human breast milk. Given the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue aprepitant therapy, taking into account the importance of the drug to the mother. In most clinical scenarios where aprepitant is used (i.e. during active chemotherapy), breastfeeding would typically not be recommended regardless of antiemetic use.

How Does Aprepitant Medical Valley Interact with Other Drugs?

Quick Answer: Aprepitant is metabolised by CYP3A4 and is a moderate inhibitor and mild inducer of CYP3A4. It also induces CYP2C9. This means it can increase or decrease the plasma levels of many co-administered medications. The most clinically important interactions involve corticosteroids (dose reduction required), warfarin (INR monitoring required), and hormonal contraceptives (efficacy may be reduced).

Drug interactions are one of the most clinically important aspects of aprepitant therapy. Aprepitant is metabolised primarily by the cytochrome P450 enzyme CYP3A4, and to a minor extent by CYP1A2 and CYP2C19. Crucially, aprepitant has a dual effect on CYP3A4: it acts as a moderate inhibitor of CYP3A4 during the 3-day dosing period, and subsequently becomes a mild inducer of CYP3A4 after the treatment course is completed. This means that aprepitant can first increase and then decrease the plasma concentrations of drugs that are CYP3A4 substrates. Additionally, aprepitant is an inducer of CYP2C9, which affects the metabolism of several important drugs including warfarin and tolbutamide.

All patients starting aprepitant should have a thorough medication review performed by their oncologist or pharmacist. The following table summarises the most clinically significant drug interactions.

Major Interactions

Minor Interactions

Several other drugs have clinically less significant but noteworthy interactions with aprepitant:

• 5-HT3 receptor antagonists (ondansetron, granisetron, palonosetron): No clinically significant pharmacokinetic interaction. These drugs are routinely co-administered with aprepitant as part of the standard antiemetic regimen. No dose adjustment is needed.
• Docetaxel, vinorelbine, and other CYP3A4-metabolised chemotherapy agents: In clinical studies, aprepitant did not significantly alter the pharmacokinetics of docetaxel or vinorelbine. However, theoretical interactions exist, and close monitoring is advisable when combining aprepitant with CYP3A4-metabolised cytotoxic agents.
• Benzodiazepines (midazolam, triazolam): Aprepitant can increase plasma concentrations of orally administered midazolam (approximately 2.3-fold increase in AUC). Patients should be monitored for increased sedation.
• Phenytoin and other CYP2C9 substrates (tolbutamide): CYP2C9 induction may reduce levels of these substrates. Monitor phenytoin levels when aprepitant is co-administered.
• Digoxin: No significant pharmacokinetic interaction has been observed. No dose adjustment is required.

What Is the Correct Dosage of Aprepitant Medical Valley?

Quick Answer: For highly emetogenic chemotherapy, the standard adult regimen is 125 mg on Day 1 (1 hour before chemotherapy) followed by 80 mg once daily on Days 2 and 3. For postoperative nausea, a single 40 mg dose is given within 3 hours before anaesthesia. The capsules can be taken with or without food and should be swallowed whole with water.

The dosing of aprepitant follows well-established regimens derived from pivotal clinical trials and endorsed by international antiemetic guidelines. The dosing schedule varies depending on the clinical indication (CINV prevention versus PONV prevention) and the emetogenicity of the chemotherapy regimen. It is critical to understand that aprepitant is always used as part of a combination antiemetic regimen – it is not intended as monotherapy for the prevention of nausea and vomiting.

Adults – Highly Emetogenic Chemotherapy (HEC)

Adults – Moderately Emetogenic Chemotherapy (MEC)

For moderately emetogenic chemotherapy regimens, the same 3-day aprepitant schedule is used (125 mg Day 1, 80 mg Days 2-3) in combination with a 5-HT3 antagonist and dexamethasone. The dexamethasone dose is similarly reduced due to the CYP3A4 interaction. Some guidelines recommend continuing aprepitant for only the duration of emetogenic risk, which may vary depending on the specific chemotherapy agents used.

Adults – Postoperative Nausea and Vomiting (PONV)

Children and Adolescents

For paediatric patients aged 12 years and older who weigh at least 6 kg and can swallow capsules, the same dosing regimen as adults may be used: 125 mg on Day 1 and 80 mg on Days 2 and 3. For younger children (6 months to <12 years) or those unable to swallow capsules, an oral suspension formulation with weight-based dosing is preferred. The treating paediatric oncologist will determine the appropriate formulation and dose.

Elderly Patients

No dose adjustment is required for elderly patients. In pivotal clinical trials, a substantial proportion of enrolled patients were aged 65 years and older, and no overall differences in safety or efficacy were observed between elderly and younger adult patients. However, as with any medication in the elderly, close monitoring is advisable given the higher likelihood of concomitant medications and comorbidities.

Missed Dose

If you forget to take a dose of aprepitant, contact your doctor or pharmacist for guidance. Because aprepitant is typically used as a short 3-day course timed around chemotherapy administration, each dose is important for optimal protection. If a dose is missed on Day 2 or Day 3, it should be taken as soon as remembered on the same day. Do not take a double dose to compensate for a missed dose. If a dose is missed entirely, do not attempt to make up for it on the following day – simply resume the scheduled dosing.

Overdose

There is no specific antidote for aprepitant overdose. In clinical studies, single doses up to 600 mg were generally well tolerated. In the event of overdose, standard supportive measures should be instituted as clinically indicated. Aprepitant cannot be removed by haemodialysis due to its high protein binding (greater than 95%). Symptoms of overdose may include drowsiness and headache. Medical attention should be sought in all cases of suspected overdose.

What Are the Side Effects of Aprepitant Medical Valley?

Quick Answer: The most common side effects of aprepitant include hiccups, fatigue, loss of appetite, constipation, headache, and diarrhoea. These are generally mild and self-limiting. Serious side effects are rare but can include severe allergic reactions (anaphylaxis, Stevens-Johnson syndrome) and liver enzyme elevations.

Aprepitant is generally well tolerated, and the side effect profile has been extensively characterised in large, randomised controlled clinical trials involving thousands of patients receiving chemotherapy. It is important to note that patients receiving aprepitant are simultaneously undergoing chemotherapy and receiving other antiemetic medications (dexamethasone, 5-HT3 antagonists), which makes it challenging to attribute specific adverse events solely to aprepitant. The following frequency classifications are based on pooled data from clinical trials and post-marketing surveillance.

Side effects are classified according to the Medical Dictionary for Regulatory Activities (MedDRA) system organ classes and the following frequency convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (<1/1,000). Understanding the frequency of potential side effects helps patients and clinicians make informed decisions about treatment and know when to seek medical advice.

It should be emphasised that the overall incidence of adverse events attributable to aprepitant in clinical trials was only slightly higher than placebo when added to standard antiemetic therapy. The most significant clinical benefit – a substantial reduction in nausea and vomiting – generally far outweighs the risk of these mostly mild and transient side effects. Patients experiencing bothersome side effects should discuss them with their oncologist, who can advise on management strategies without compromising antiemetic protection.

How Should You Store Aprepitant Medical Valley?

Quick Answer: Store aprepitant capsules at room temperature (below 30°C) in the original packaging to protect from moisture and light. Keep out of reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of aprepitant is essential to ensure that the medication retains its full potency and safety throughout its shelf life. Incorrect storage can degrade the active ingredient or alter the dissolution properties of the capsule, potentially affecting how well the medication works.

Store the capsules at room temperature, ideally below 30°C (86°F). The capsules should be kept in their original blister packaging until the time of use, as this provides protection from moisture and light. Aprepitant capsules are sensitive to humidity, and exposure to excessive moisture can affect the stability of the formulation. Do not transfer the capsules to pill organisers or other containers that do not provide equivalent moisture protection.

Keep the medication out of the sight and reach of children. Do not use Aprepitant Medical Valley after the expiry date stated on the blister and carton. The expiry date refers to the last day of that month. Do not dispose of unused medications in household waste or wastewater. Return any unused capsules to your pharmacist for safe disposal in accordance with local environmental regulations.

What Does Aprepitant Medical Valley Contain?

Quick Answer: Each hard capsule contains either 80 mg or 125 mg of aprepitant as the active substance. The capsules also contain inactive ingredients (excipients) necessary for the formulation, including sucrose, microcrystalline cellulose, hydroxypropylcellulose, and sodium lauryl sulphate.

Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to any pharmaceutical excipients. Aprepitant Medical Valley is available as hard capsules for oral administration.

Active Substance

The active ingredient in Aprepitant Medical Valley is aprepitant. Each capsule contains either 80 mg or 125 mg of aprepitant. Aprepitant is a white to off-white crystalline powder that is practically insoluble in water. To improve bioavailability, aprepitant is formulated using a nanoparticle technology or similar formulation approach that reduces the particle size, thereby increasing the surface area available for dissolution and absorption in the gastrointestinal tract.

Excipients (Inactive Ingredients)

The capsule formulation typically contains the following excipients, though the exact composition may vary between manufacturers and regulatory markets:

• Sucrose: Used as a carrier and bulking agent. Patients with rare hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should be aware of this ingredient.
• Microcrystalline cellulose: A commonly used pharmaceutical excipient that serves as a binder and filler.
• Hydroxypropylcellulose: A cellulose derivative used as a binder and film-forming agent.
• Sodium lauryl sulphate: A surfactant that aids in the dissolution and absorption of the active ingredient.
• Capsule shell components: The hard gelatin capsule shell typically contains gelatin, titanium dioxide (E171), and may contain additional colorants depending on the capsule strength. The 80 mg capsule and 125 mg capsule are usually different colours for easy identification.

If you have any allergies or dietary restrictions that may be affected by these excipients (for example, gelatin in the capsule shell may be unsuitable for certain dietary or religious practices), discuss this with your pharmacist. In some cases, the prescribing physician may be able to recommend an alternative formulation or brand.

Frequently Asked Questions About Aprepitant Medical Valley

References

Editorial Team